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A B S T R A C T   
Lemierre syndrome is a rare but potentially fatal condition characterized by septic thrombophlebitis of the head 
and neck district, preferentially affecting adolescents and young adults and manifesting as a complication of a 
local bacterial infection – typically, a pharyngotonsillitis or an abscess. It is historically associated with the 
Gram-negative anaerobic rod Fusobacterium necrophorum and with thrombophlebitis of the internal jugular vein. 
However, its definition has never been firmly established, and its spectrum within the continuum of bacteria- 
associated thrombophlebitis may be larger than what presumed so far. Recent evidence suggests that its prog-
nosis remains serious even one hundred years after its first description, with considerable rates of in-hospital 
complications, death, and long-term sequelae. There are no specific guidelines on its management other than 
usual antibiotic stewardship, with ongoing debate on the potential role of therapeutic-dose anticoagulation. 
We provide an overview of current evidence on the definition, epidemiology, clinical presentation, prognosis 
and management of this condition and present the background and rationale of the Bacteria-Associated 
Thrombosis/Thrombophlebitis and LEmierre syndrome (BATTLE) registry: an ambispective, disease-specific, 
non-population based, multicentre clinical registry of global reach and multidisciplinary scope, specifically 
designed to address the limitations of current evidence and to provide patients and physicians with clinically 
viable information to guide management and improve the outcomes of those affected by these conditions.   
1. Current evidence on Lemierre syndrome 
First described approximately one century ago, Lemierre syndrome, 
a rare, but potentially fatal form of septic thrombophlebitis, is still 
poorly understood. With evidence suggesting that its prognosis remains 
serious and its incidence, or at least the global awareness on it, is in-
creasing, more reliable data to guide its clinical management are ur-
gently needed. We provide an overview of the current state of evidence 
on this condition and present the rationale of the international Bacteria- 
Associated Thrombosis/Thrombophlebitis and LEmierre syndrome 
(BATTLE) registry. 
1.1. Definition, physiopathology, and epidemiology 
In 1900, the French physicians Courmont and Cade were the first to 
characterise a condition in which anaerobic bacteria caused an 
oropharyngeal infection, gained intravascular access, and produced 
septic pulmonary infarcts [1]. Subsequently, the Americans Goldman 
and Mosher (1917–1920) and the German Fränkel (1925) specifically 
described the transition from an initial tonsillitis to thrombophlebitis of 
the tonsillar veins, a septic thrombus in the internal jugular vein, and its 
fragmentation in septic emboli. However, they could not identify the 
causative agent conclusively [2,3]. Fränkel's article was referenced by 
the Parisian professor André Lemierre (Fig. 1) in his description of 20 
cases published in the Lancet in 1936, which ultimately resulted in the 
eponym Lemierre syndrome from the 1980s at the earliest [4,5]. Le-
mierre's patients were otherwise healthy adolescents and young adults 
affected by a head or neck infection, often a peritonsillar, para-
pharyngeal or retropharyngeal abscess mimicking a simple tonsillitis, 
which was indeed complicated by local venous thrombosis – typically of 
the internal jugular vein, ultimately unleashing multiple peripheral 
septic emboli with subsequent abscess formation, especially in the lungs 
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and the joints. Lemierre observed the co-occurrence of all individual 
disease stages and findings reported separately by his predecessors, 
confirming that the agent most frequently responsible for the syndrome 
was an anaerobic Gram-negative rod then mostly known as Bacillus 
funduliformis, which would be later renamed Fusobacterium necro-
phorum. 
How the infection spreads from its initial focus to the intravascular 
space is uncertain. The early notion that the typical primary infection 
was a tonsillitis and the thrombus was usually located in the internal 
jugular vein initially suggested that bacteria spread through the ton-
sillar and peritonsillar veins [6]. As it became clear that other head or 
neck infections can cause the syndrome and that other vessels, in-
cluding the external jugular vein or the facial vein, may be involved, 
other pathways were postulated, including direct extension through the 
fascial plane between the tonsils and the parapharyngeal space and 
lymphatic spread [7]. All reports from the twentieth century confirmed 
the syndrome's specific association with Fusobacterium necrophorum. 
Well-known in veterinary medicine because of the serious suppurative 
infections caused by subspecies necrophorum (biotype A) in cattle, this 
organism is most commonly found in the human oropharyngeal, gas-
trointestinal and female genital flora as subspecies funduliforme (bio-
type B) [5,8]. The latter subspecies' ability to cause invasive infections 
(necrobacillosis) with thrombophlebitis and distant abscess formation 
has been attributed to its numerous virulence factors. Fusobacterium 
necrophorum funduliforme can adhere to epithelial cells [9] and pene-
trate tissues by converting plasminogen into the fibrinolytic enzyme 
plasmin [10]. It may be able to evade the innate immune system by 
binding factor H [11] and by secreting a protein that inhibits leukocyte 
migration toward the site of infection [12]. Its ability to promote 
thrombus formation has been attributed to its hemagglutinin [12], 
which promotes platelet aggregation, or to direct activation of the 
contact system [13], and may also have evolved as a mean to stave off 
immune cells while promoting a locally anaerobic environment [12]. 
Heparinase may then precipitate septic embolization [14,15]. Several 
of these properties, however, are shared by other members of the same 
genus, such as Fusobacterium nucleatum, increasingly studied over the 
last few years because of its association with parodontitis and several 
gastrointestinal diseases [16], as well as by other genera, namely Sta-
phylococcus spp., Streptococcus spp. and Bacteroides spp., frequently 
isolated in patients with Lemierre syndrome and cultures negative for 
Fusobacterium spp. [12,17]. 
Three criteria are historically used to diagnose Lemierre syndrome: 
(i) a primary site of infection located in the head or neck (typically, 
history of sore throat or anginal illness); (ii) a thrombosis or throm-
bophlebitis of the internal jugular vein or other vein of the head/neck 
district, or metastatic lesions (sometimes listed as two separate cri-
teria); (iii) the isolation of F. necrophorum from blood culture or a 
normally sterile site. This definition is the result of considerable his-
torical evolution [5]. While some debate remains as to whether diag-
nosis of Lemierre syndrome requires an oropharyngeal infection (rather 
than any infection of the head/neck district), cases of thrombosis or 
septic embolism from Fusobacterium spp. septicemia originating from 
foci outside the head and neck are generally excluded or described as 
“atypical” or “variant” Lemierre syndrome. There is now substantial 
consensus that a thrombus in the internal jugular vein does not need to 
be demonstrated, because a clot at this site may be easily missed, and, 
when present, does not seem to persist over the whole clinical course 
[5]. Similarly, the isolation of Fusobacterium spp. is not considered to be 
mandatory: this organism is difficult to isolate, cultures may be nega-
tive due to empiric antibiotic therapy, and other bacteria seem able to 
cause Lemierre syndrome [5,17]. In a recent analysis of 712 cases re-
ported in the scientific and grey literature since 2000, which were 
identified using the commonly applied broad definition [7], the cases 
satisfying the “typical” definition (oropharyngeal infection and isola-
tion of Fusobacterium spp.) only represented approximately half of the 
observed spectrum of the syndrome; Fig. 2 [18]. Therefore, the clinical 
definition of Lemierre syndrome may be considered a specific mani-
festation of the continuum represented by bacterial thrombophlebitis, 
Fig. 1. Dr. André Lemierre (1875–1956), professor of Bacteriology and Infectious Diseases in Paris. 
Source: gallica.bnf.fr; Bibliothéque Nationale de France/Agence Rol. 
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which includes conditions associated with diverse primary infections 
caused by several microbiological agents [17]. 
Lemierre syndrome is rare, but its incidence is unknown. Estimates 
based on country-wide or regional retrospective analyses of data from 
microbiology laboratories suggest an annual incidence ranging from 0.8 
to 3.6 cases/million population. [19–22] However, this condition is 
remarkably specific to adolescents and young adults. In these age 
groups, estimates of the annual incidence were considerably higher, 
reaching 14.4 cases/million population aged 14 to 25 years (Denmark, 
1998–2001) [19] and 16 cases/million population aged 15 to 19 years 
(Sweden, 2017) [22]. Why the syndrome affects these age groups so 
specifically remains a mystery. Early hypotheses attribute the age dis-
tribution to the change from a predominantly aerobic to a pre-
dominantly anaerobic oral flora between late childhood and adoles-
cence, or the formation of the deep tonsillar crypts after the regression 
of tonsillar tissue known to occur around this age. Either would cause 
the immune system to be first exposed to certain anaerobe infections 
only at this time, with a temporarily heightened risk of occasional in-
vasive infection until adequate adaptive immunity is developed within 
a few years [23]. The potential role of Epstein-Barr Virus infection or 
thrombophilia, which display age distributions at least partially over-
lapping that of Lemierre syndrome, has never been proved conclusively 
because of limitations in the case definition, small sample sizes, poor 
case-mix, the absence of control groups, and the difficulty to exclude 
confounding [5,6,24]. 
The above-mentioned incidence studies identified cases based on 
positive cultures for Fusobacterium necrophorum, with the explicit ex-
clusion of clinical cases of Lemierre syndrome with no growth of 
Fusobacterium even when they were documented [19], and in one study 
the case definition was further limited to a primary oropharyngeal focus 
[21]. As such, their figures only refer to the incidence of the “typical” 
definition and may underestimate the incidence of the condition in its 
broad clinical definition. 
Several Authors have reported a decreased incidence of Lemierre 
syndrome between the 1950s and the 1970s, followed by a resurgence 
from the 1980s onwards [6]. These trends have been attributed to the 
increased use of antibiotic therapy in pharyngotonsillitis before the 
1980s, followed by its progressive restriction in guidelines for primary 
care [21]; to the decreasing use of tonsillectomy [5]; or even to the 
disruption of nasopharyngeal flora by the introduction of pneumococcal 
vaccination [25]. Until recently, the claims of an increasing incidence 
were difficult to substantiate, as they were mainly based on the number 
of absolute reports in the scientific literature, single-centre series, or 
epidemiological studies of necrobacillosis (septicemia from Fuso-
bacterium necrophorum) rather than Lemierre syndrome [26]. However, 
since 2000, the number of reported cases or publications also increased 
as a proportion of all scientific publications (as estimated by those re-
ported on the Medline repository) [18]. The most recent nationwide 
study of Fusobacterium-associated cases confirmed an increasing trend 
from 2010 to 2017 in Sweden [22]. 
1.2. Clinical presentation, prognosis, and treatment 
Most patients present with sepsis, neck swelling and tenderness, or 
both, typically a few days or weeks after an oropharyngeal illness. The 
latter has often already resolved by the time the patient's condition 
requires the medical attention that ultimately leads to diagnosis [6]. 
However, neither sepsis nor neck-specific signs and symptoms are 
highly sensitive or specific. Moreover, multi-organ involvement is al-
ready present at diagnosis, with over 80% of patients displaying septic 
embolism, especially pulmonary, musculoskeletal, or intracranial [18]. 
As a consequence, differential diagnosis is usually complex; depending 
on the dominant features at presentation, it may include conditions 
ranging from relatively common conditions such as streptococcal 
pharyngitis, viral infection (infectious mononucleosis, CMV), septic 
arthritis, meningitis, or community-acquired pneumonia [27,28] to 
leptospirosis, toxic shock syndrome, catastrophic anti-phospholipid 









Fig. 2. Proportional area chart of the distribution of the traditional criteria for Lemierre syndrome in 712 cases described from 2000 to 2017. All patients had a 
primary head/neck infection and head/neck thrombosis or septic embolism, but only about half satisfied the typical definition of Fusobacterium spp.-associated, post- 
anginal thrombosis or septic embolism. 
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Frequently, the diagnosis is only considered after the incidental isola-
tion of Fusobacterium necrophorum, which may lead to potentially 
clinically relevant delay of the appropriate management [33]. There-
fore, a high index of suspicion is necessary to diagnose Lemierre syn-
drome. Awareness of the existence of the syndrome, especially in the 
setting of primary and acute care, may be essential to ensure a timely 
diagnosis. In the era of Internet and Big Data, prompt availability of 
large volumes of information or automated support to diagnosis may 
further contribute to the evolution of patterns of recognition and di-
agnosis. 
Fatal outcome was common in the pre-antibiotic era. In the original 
series described by Lemierre, 18 out of 20 patients died. Subsequent 
series described decreasing fatality rates, with estimates over the last 
20 years stable around 5% [18,34]. The analysis of cases described after 
2000 provided the first estimates of the rate of in-hospital complica-
tions and long-term sequelae. More than 14% of the patients suffered 
new, recurrent, or worsening venous thromboembolism or peripheral 
septic lesions, whereas 12% of the survivors experienced post-discharge 
recurrence or clinical sequelae, including neurologic impairment such 
as cranial nerve palsy, blindness, paralysis or paresis, or orthopaedic 
and functional limitations. Patients with involvement of the central 
nervous system at baseline and those who did not receive antic-
oagulation therapy had more often in-hospital complications [18]. 
Over 90% of patients are treated with multiple antibiotics over their 
clinical course. Surgical treatment is often necessary, and internal vein 
ligation is still performed in cases with septic embolization refractory to 
medical therapy, albeit less often than in older series [18]. The use of 
anticoagulation in Lemierre syndrome has been the object of con-
siderable controversy. While anticoagulant treatment is considered 
potentially valuable in containing the initial septic thrombus and to 
prevent extension or recurrence of venous thromboembolism, espe-
cially intracranially [35], clinicians often refrain from it because of the 
possibility that septic emboli may be unleashed from the primary 
thrombus, and because thrombocytopenia or tissue damage by septic 
emboli may increase the risk of bleeding. The most recent and largest 
analysis showed that the anticoagulant-related bleeding was sporadic, 
suggesting that Lemierre syndrome may not represent a specific trigger 
for bleeding complications [18]. Although these data were observa-
tional and do not permit any conclusion on causality or treatment ef-
ficacy, it is hard to find a rationale to depart from international 
guidelines suggesting in-hospital thromboprophylaxis for bedridden 
patient with an acute inflammatory disease and recommending routine 
anticoagulant treatment of acute venous thromboembolism. Any de-
viation from this approach should, in our opinion, represent an ex-
ception and be decided on an individual level basis until higher-level 
clinical evidence becomes available. This seems particularly appro-
priate in light of the apparently high rate of new thrombotic compli-
cations seen in hospitalized patients with Lemierre syndrome even after 
the initiation of antibiotic treatment. 
2. The international Bacteria-Associated Thrombosis/ 
Thrombophlebitis and LEmierre syndrome (BATTLE) registry 
2.1. Background and aims 
The primary analysis of individual patient data of patients described 
after 2000 provided an estimate of the burden and clinical complexity 
of Lemierre syndrome in the contemporary era, confirmed it as an in-
herently thrombotic disease from a clinical standpoint, and established 
that its pathophysiological and clinical spectrum considerably overlap 
with other forms of bacteria-associated septic thrombophlebitis 
[7,17,18]. However, these findings may still be sensitive to reporting 
and detection bias. In order to provide guidance for patient manage-
ment, they need to be integrated by higher-quality evidence as re-
presented by a multicentre collection of consecutive patients, with cases 
identified based on a standardized definition, and relying on structured 
data entry. These data would serve to address several open issues in the 
clinical course of Lemierre syndrome, including the impact of key 
predictors of severity on patient outcomes, the patterns of involvement 
of vital organs – namely, the central nervous system, and the potential 
impact of anticoagulation. Such information would be especially useful 
in paediatric patients, for whom evidence is limited even on the overall 
diagnosis and management of acute venous thromboembolism. The 
epidemiological significance of Lemierre syndrome, its burden and its 
microbiological basis may also have far-reaching consequences on the 
clinical management of head/neck infections of adolescents and young 
adults in primary care. Current guidelines are still largely influenced by 
the priority of preventing rheumatic fever associated with group A β- 
haemolytic streptococcal pharyngitis; this goal may be outdated in light 
of the currently estimated incidence and severity of this condition, 
especially compared with the complications of Fusobacterium phar-
yngotonsillitis [36]. In this respect, a focused analysis of the overall 
burden of Lemierre syndrome in adolescents and young adults, in-
cluding the long-term impact on survivors and its pharmacoeconomic 
implications, may provide a valuable contribution. 
With these aims, we designed the Bacteria-Associated Thrombosis/ 
Thrombophlebitis and LEmierre syndrome (BATTLE) registry. Its ulti-
mate goal is to improve the care of patients with bacterial throm-
bophlebitis, with a focus on Lemierre syndrome. Its primary objective is 
to advance the extent and level of the evidence that currently serves to 
guide clinical management, and support the development of guidelines 
and consensus documents. Specifically, the registry will  
1. identify potential improvements in the diagnostic pathway, possibly 
leading to a reduced diagnostic delay;  
2. identify clinically relevant prognostic tools for patients diagnosed 
with Lemierre syndrome; 
3. evaluate the use of antibiotic therapies and anticoagulation treat-
ment in Lemierre syndrome, both by directly providing real-world 
observational data and by generating information necessary to plan 
future interventional studies;  
4. assess long-term functional status, quality of life, and self-sufficiency 
in survivors of Lemierre syndrome with a focus on standardized, 
validated patient-reported outcome measures. 
2.2. Design 
The BATTLE registry is a disease-specific, non-population based, 
multicentre clinical registry with ambispective, electronic data collec-
tion. It will include patients who satisfy the criteria for bacteria-asso-
ciated thrombosis or thrombophlebitis or the subset of criteria for 
Lemierre syndrome (Table 1). 
Its stakeholders will include patients, clinicians, researchers and 
scientific associations promoting research in thromboembolic, in-
fectious, and paediatric diseases. Inclusion in the registry does not 
dictate any diagnostic or therapeutic interventions, and patients will be 
treated by applying current local or international guidelines at the 
discretion of the treating physicians. 
The registry is designed in accordance with the recent re-
commendations of the experts of the RD-Connect project [37], which 
integrate field expertise with the FAIR framework for management and 
stewardship of scientific data [38] and the international guidelines 
provided by the United States Agency for Healthcare Research and 
Quality [39] and the European Commission's Joint Research Centre 
[40]. 
Data collection will be based on an electronic Case Report Form that 
secondarily collects information provided by the treating physician, and 
the main database maintained on a web-based infrastructure [41]. Its 
items include the European Commission's set of common data elements 
for Rare Diseases Registration [40] and are standardized based on the 
World Health Organization's international standards Anatomical Ther-
apeutic Chemical Classification [42] and International Statistical 
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Classification of Diseases and Related Health Problems [43]. Quality 
assurance will be ensured by an integrity check upon data entry, quality 
control on periodic internal validation for clinical face validity and 
analytical internal validity. 
2.3. Governance 
The BATTLE registry is an independent, investigator-initiated study. 
The investigators are responsible for the design, conduct, and analysis 
of the registry data. The study has an academic sponsor (University 
Medical Center of the Johannes Gutenberg University, Mainz, 
Germany). Funding for its establishment and initial operational costs 
was provided by an award assigned by the Gesellschaft für Thrombose- 
und Hämostaseforschung (GTH) for the research project “Clinical pre-
sentation, treatment and course of Lemierre syndrome and bacterial- 
associated venous thromboembolism in children and adolescents”. 
Ethical approval and registration on ClinicalTrials.gov are pending. 
The registry's core team, its administrative support, and the main 
web-based portal (www.battle-registry.org) are based at the Center for 
Thrombosis and Hemostasis at the University Medical Center of the 
Johannes Gutenberg University of Mainz. 
The registry complies with the principles of Ethical, Legal and 
Societal Issues [37]. Patient confidentiality will be ensured by pseu-
donymization, and separate informed consent will be provided as re-
quired. The reason of all patient withdrawals will be documented. If an 
informed consent for follow-up has been signed, the patient's family 
physician will be contacted if a personal contact is not possible. 
Transparency will be guaranteed by access rules and duties set forth in a 
publicly available statement of intellectual property and a Data 
Transfer Agreement. 
2.4. Innovative features over available evidence 
The BATTLE registry specifically addresses the limitations of current 
evidence on Lemierre syndrome and bacteria-associated thrombosis and 
thrombophlebitis. These conditions are rare, difficult to diagnose and of 
uncertain definition. As a consequence, available information is limited 
to case reports or single-centre series, which makes current evidence 
vulnerable to sampling, reporting, and publication bias. These issues 
have made it particularly difficult to draw definite conclusions on the 
role of potentially clinically relevant comorbidities and risk factors: in 
the absence of control groups, associations with risk factors were pos-
tulated or hypothesised based solely on their prevalence among ob-
served cases, a form of a posteriori conditional probability that cannot 
prove association, much less causality or prediction, and is furthermore 
subject to detection bias [24]. Compared with other rare conditions, 
case finding of patients with septic thrombophlebitis is more complex 
and case-mix bias more likely, because their clinical presentation is 
non-specific and may include multi-organ involvement, with the med-
ical specialties involved in their care varying by individual case, 
healthcare institution, and country; and because their clinical course is 
acute or subacute, with long-term follow-up of survivors possibly lim-
ited to subgroups with long-term sequelae or medical specialties outside 
critical and acute care. The following features of the BATTLE registry 
will address these limitations:  
- Comprehensive inclusion criteria to make it possible to explore 
the whole spectrum of bacterial thrombophlebitis/Lemierre syn-
drome and thus compare the scientific merits of alternative epide-
miological case definitions and the clinical value of alternative di-
agnostic criteria.  
- Ambispective design: a structured first contact will allow new 
participating centres to first retrospectively include past patients 
satisfying the inclusion criteria, and subsequently prospectively in-
clude new patients upon diagnosis or upon regular contact by the 
core committee; this will minimise reporting and detection bias.  
- Global scale: the study of rare diseases requires large networks in 
order for adequately sized samples to be reached, and poor geo-
graphic representativeness is thought to have particularly affected 
the study of Lemierre syndrome. [33] The existing network of the 
Lemierre study group, the sponsoring institution and the funding 
institutions, along with the absence of geographical limitations, will 
maximise the population size and its representativeness.  
- Multidisciplinary and multicentre network: the involvement of 
secondary and tertiary care healthcare institutions and the outreach 
to all specialties potentially involved in the care of Lemierre syn-
drome (emergency medicine and critical care, infectious diseases, 
otolaryngology, microbiology, radiology, haematology, paediatrics, 
and general internal medicine) will enhance the representativeness 
of the registry population and prevent case-mix bias. 
- Active outreach and case-finding: the core team will actively ap-
proach medical specialists belonging to specialties likely to see pa-
tients satisfying the inclusion criteria but who have so far reported 
none. This will be accomplished by the identification and active in-
vitation of specialists in academic and non-academic hospitals, and by 
participation to scientific conferences of all specialties typically in-
volved in the care of patients with septic thrombophlebitis.  
- Adherence to the FAIR data model (Findable, Accessible, 
Interoperable and Reusable) will ensure transparency, access by 
external researchers, reproducibility of research findings, and 
compatibility with other databases.  
- Pre-defined compatibility with future prospective substudies 
including long-term follow-up of patient-centred and patient-re-
ported outcomes, which are largely absent from the evidence 
available so far, focused as it was on clinical outcomes. 
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Table 1 
General inclusion criteria of the BATTLE registry.    
Bacteria-associated thrombophlebitis Lemierre syndrome subgroup  
1. Clinically diagnosed or microbiologically documented invasive bacterial infection 1. Clinically diagnosed or microbiologically documented invasive bacterial infection 
2. History or objective diagnosis of primary infection focus in the head/neck or the 
abdominopelvic district 
2. History or objective diagnosis of primary infection focus in head/neck district 
3. Objective diagnosis of thrombosis in location anatomically adjacent to the primary 
infection focus and/or septic embolism in typical location 
2. Objective diagnosis of thrombosis of the head/neck district or thromboembolism in 
locations anatomically consistent with the primary infection focus in the head/neck 
district 
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